Complete Filing Data
BIOREGENX, INC. reported Stockholders Equity of -$2.53 million for FY2022.
All values from 10-K, 20-F, and 10-Q filings on SEC EDGAR, organized by financial statement. Scroll each table horizontally for the full history. Blank cells mean BIOREGENX, INC. did not report that metric for that period in XBRL — often because accounting standards changed which tag a company files under (for example, most companies moved revenue to the ASC-606 tag in 2018), so a metric may continue in a different row. Rows marked * merge those successor tags into one continuous series, preferring the audited value from the newest-standard tag where periods overlap.
Income Statement
Annual (10-K / 20-F)
| Metric \ Fiscal Year | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|
| Comprehensive Income Net Of Tax | -$23.1M | -$3.6M | -$117.3K | -$261.9K |
| Net Income Loss | -$23.1M | -$3.6M | -$78.3K | -$96.9K |
| Revenues | $2.3M | $3.4M | $42.2K | $198.6K |
| Operating Income Loss | -$22.8M | -$3.4M | -$78.3K | -$165.1K |
| Operating Expenses | $24.4M | $5.7M | $120.5K | $363.1K |
| Gross Profit | $1.7M | $2.3M | $42.2K | $198.0K |
| Cost Of Revenue | $681.7K | $1.1M | $0.00 | $554.00 |
| Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax | $3.0K | $18.8K | ||
| Selling General And Administrative Expense | $5.9M | $5.2M | ||
| Nonoperating Income Expense | -$461.5K | $0.00 | $68.2K | |
| Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent | $3.0K | $18.8K | ||
| Sales Returns | $261.7K | $276.5K | ||
| Income Taxes Paid | $0.00 | $0.00 | ||
| Gross Revenues | $2.6M | $3.7M | ||
| Financing Interest Expense | $290.7K | $191.2K | ||
| Deferred Revenue Current | $354.2K | |||
| Income Tax Expense Benefit | $0.00 | $0.00 | $0.00 | |
| Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest | -$571.2K | -$78.3K | -$96.9K | |
| Interest Expense | $8.3K | $0.00 | ||
| Fair Value Of Common Stock And Warrants Issued For Refunds Offset To Deferred Revenue | $22.2K | $193.8K | ||
| Other General And Administrative Expense | $18.3K | $27.6K | $81.1K | |
| Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax | -$20.9K | -$39.0K | -$165.0K |
Quarterly (10-Q, single quarters)
| Metric \ Quarter | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q3 2023 | Q2 2023 | Q1 2023 | Q3 2022 | Q2 2022 | Q1 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Comprehensive Income Net Of Tax | -$73.3K | -$185.5K | -$268.9K | -$397.4K | -$1.1M | -$3.2M | -$2.5M | -$579.5K | -$527.0K | $18.2K | -$112.7K | -$17.3K | |
| Net Income Loss | -$80.6K | -$178.3K | -$266.9K | -$394.9K | -$1.1M | -$3.2M | -$2.5M | -$594.5K | -$548.0K | -$2.2K | -$33.3K | -$37.3K | |
| Revenues | $507.8K | $446.0K | $515.1K | $596.0K | $734.0K | $549.5K | $794.5K | $863.3K | $5.6K | $11.3K | $14.3K | $7.7K | |
| Operating Income Loss | -$8.5K | -$107.3K | -$192.6K | -$327.3K | -$1.0M | -$3.1M | -$2.5M | -$544.6K | -$92.8K | -$2.2K | -$33.3K | -$37.3K | |
| Operating Expenses | $434.9K | $459.7K | $598.6K | $809.0K | $1.5M | $3.5M | $3.0M | $1.1M | $98.3K | $13.5K | $47.5K | $45.0K | |
| Gross Profit | $426.4K | $352.5K | $406.0K | $481.6K | $469.9K | $384.2K | $571.2K | $598.3K | |||||
| Cost Of Revenue | $81.4K | $93.5K | $109.1K | $114.4K | $264.2K | $165.4K | $223.3K | $265.0K | |||||
| Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax | $7.2K | -$7.2K | -$2.1K | -$2.6K | $518.00 | $1.0K | $0.00 | $14.9K | |||||
| Selling General And Administrative Expense | $432.5K | $456.7K | $590.4K | $236.3K | $1.4M | $3.4M | $3.0M | $1.0M | |||||
| Nonoperating Income Expense | -$67.6K | -$66.3K | -$50.5K | -$49.8K | -$455.3K | $0.00 | $0.00 | $0.00 | |||||
| Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent | $7.2K | -$7.2K | -$2.1K | -$2.6K | $519.00 | $1.0K | $14.9K | ||||||
| Sales Returns | $1.8K | $814.00 | $1.3K | $473.00 | $123.5K | $135.4K | $5.6K | ||||||
| Income Taxes Paid | $0.00 | $0.00 | |||||||||||
| Gross Revenues | $509.5K | $446.8K | $516.5K | $596.5K | $857.5K | $684.9K | $800.1K | ||||||
| Financing Interest Expense | $74.2K | $67.6K | $66.3K | $73.0K | $50.5K | $49.8K | |||||||
| Deferred Revenue Current | $95.8K | $125.2K | $189.3K | $197.0K | $165.6K | $195.9K | |||||||
| Income Tax Expense Benefit | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | |||||||
| Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest | -$3.7K | -$4.1K | -$548.0K | -$2.2K | -$33.3K | -$37.3K | |||||||
| Interest Expense | $71.1K | $66.3K | $2.0K | $2.1K | $2.0K | $0.00 | $0.00 | $0.00 | |||||
| Fair Value Of Common Stock And Warrants Issued For Refunds Offset To Deferred Revenue | $0.00 | $22.2K | |||||||||||
| Other General And Administrative Expense | $1.0K | $1.9K | $9.2K | $6.4K | $7.9K | $6.6K | |||||||
| Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax | -$50.8K | $9.0K | $21.0K | $20.4K | -$79.4K | $20.0K |
Balance Sheet
Annual (10-K / 20-F)
| Metric \ Fiscal Year | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|
| Stockholders Equity | -$2.5M | -$84.2K | $177.6K | ||
| Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents | $616.7K | $24.4K | $93.9K | ||
| Retained Earnings Accumulated Deficit | -$12.5M | -$2.9M | -$2.8M | ||
| Liabilities Current | $2.8M | $64.9K | $14.2K | ||
| Liabilities And Stockholders Equity | $865.8K | $59.1K | $127.8K | ||
| Liabilities | $2.9M | $260.7K | $212.0K | ||
| Common Stock Value | $770.8K | $269.7K | $269.7K | ||
| Assets Current | $652.7K | $676.00 | $24.4K | ||
| Assets | $865.8K | $59.1K | $127.8K | ||
| Finite Lived Intangible Assets Net | $49.4K | $37.5K | $43.4K | ||
| Property Plant And Equipment Net | $13.7K | ||||
| Prepaid Expense And Other Assets Current | $205.2K | ||||
| Notes And Loans Payable Current | $375.7K | ||||
| Long Term Notes Payable | $150.0K | ||||
| Inventory Net | $217.5K | ||||
| Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect | -$67.0K | -$491.3K | |||
| Accrued Liabilities Current | $346.7K | ||||
| Accounts Receivable Net Current | $104.6K | ||||
| Accounts Payable Current | $241.7K | ||||
| Accumulated Other Comprehensive Income Loss Net Of Tax | -$942.00 | ||||
| Repayments Of Related Party Debt | $0.00 | $191.0K | $700.00 | $0.00 | |
| Fair Value Of Common Stock Issued For Intangible Property And Equipment In Acquisition Of Docsun Biomedical Holdings Inc. | $10.7M | $0.00 | |||
| Debt Default Shortterm Debt Amount | $322.5K | ||||
| Notes Payable And Loans Related Parties Current | $963.2K | ||||
| Fair Value Of Common Stock And Warrants Issued For Loan Fees Offset To Loan Discounts | $21.3K | $0.00 |
Quarterly (10-Q, single quarters)
| Metric \ Quarter | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q3 2022 | Q2 2022 | Q1 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Stockholders Equity | -$3.6M | -$3.7M | -$3.6M | -$3.4M | $13.6M | $14.2M | $15.1M | -$2.1M | -$2.8M | -$2.6M | -$2.4M | -$196.0K | -$214.2K | -$101.6K |
| Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents | $46.9K | $46.5K | $83.6K | $58.4K | $70.1K | $57.4K | $114.2K | $125.4K | $58.0K | $225.3K | $0.00 | $1.5K | $2.1K | $3.4K |
| Retained Earnings Accumulated Deficit | -$36.1M | -$36.0M | -$35.8M | -$35.6M | -$17.2M | -$16.8M | -$3.5M | -$3.4M | -$3.4M | |||||
| Liabilities Current | $3.9M | $3.9M | $3.8M | $3.6M | $3.5M | $3.4M | $240.5K | $41.8K | $39.1K | |||||
| Liabilities And Stockholders Equity | $1.2M | $1.2M | $482.6K | $508.5K | $17.4M | $17.9M | $34.0K | $85.5K | $78.0K | |||||
| Liabilities | $4.8M | $4.8M | $4.0M | $3.9M | $3.8M | $3.7M | $240.5K | $237.6K | $234.9K | |||||
| Common Stock Value | $962.0K | $961.2K | $960.3K | $957.0K | $956.5K | $956.5K | $276.8K | $276.8K | $276.8K | |||||
| Assets Current | $273.2K | $249.6K | $294.3K | $307.8K | $371.0K | $326.1K | $758.00 | $0.00 | $0.00 | |||||
| Assets | $1.2M | $1.2M | $482.6K | $508.5K | $17.4M | $17.9M | $34.0K | $85.5K | $78.0K | |||||
| Finite Lived Intangible Assets Net | $725.0K | $725.0K | $0.00 | $9.7M | $10.2M | $33.0K | $34.5K | $36.0K | ||||||
| Property Plant And Equipment Net | $169.6K | $176.0K | $188.4K | $200.7K | $213.1K | $225.5K | ||||||||
| Prepaid Expense And Other Assets Current | $54.2K | $47.8K | $59.0K | $123.3K | $122.8K | $113.8K | ||||||||
| Notes And Loans Payable Current | $1.0M | $970.1K | $880.8K | $883.3K | $875.5K | $850.8K | ||||||||
| Long Term Notes Payable | $181.1K | $179.7K | $257.2K | $254.6K | $282.3K | $249.6K | ||||||||
| Inventory Net | $109.4K | $134.2K | $140.4K | $111.1K | $158.7K | $143.9K | ||||||||
| Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect | $25.2K | -$11.2K | ||||||||||||
| Accrued Liabilities Current | $380.6K | $405.5K | $514.5K | $453.0K | $426.7K | $398.1K | ||||||||
| Accounts Receivable Net Current | $62.6K | $21.1K | $11.2K | $15.0K | $19.4K | $10.9K | ||||||||
| Accounts Payable Current | $459.7K | $568.8K | $490.8K | $427.5K | $492.7K | $431.8K | ||||||||
| Accumulated Other Comprehensive Income Loss Net Of Tax | -$7.2K | -$25.00 | $2.0K | -$1.9K | $618.00 | |||||||||
| Repayments Of Related Party Debt | $110.00 | $0.00 | ||||||||||||
| Fair Value Of Common Stock Issued For Intangible Property And Equipment In Acquisition Of Docsun Biomedical Holdings Inc. | $0.00 | $10.7M | ||||||||||||
| Debt Default Shortterm Debt Amount | $522.5K | $522.5K | $522.5K | $522.5K | $522.5K | $522.5K | ||||||||
| Notes Payable And Loans Related Parties Current | $1.0M | $1.0M | $1.0M | $1.0M | $995.3K | $995.3K | ||||||||
| Fair Value Of Common Stock And Warrants Issued For Loan Fees Offset To Loan Discounts | $0.00 | $20.0K |
Cash Flow Statement
Annual (10-K / 20-F)
| Metric \ Fiscal Year | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|
| Net Cash Provided By Used In Operating Activities | -$324.1K | -$1.5M | -$64.7K | -$119.5K |
| Net Cash Provided By Used In Investing Activities | -$187.9K | -$199.4K | $0.00 | $0.00 |
| Net Cash Provided By Used In Financing Activities | $442.1K | $1.2M | $41.0K | $50.0K |
| Increase Decrease In Deferred Revenue | -$135.0K | -$80.6K | $0.00 | -$7.0K |
| Increase Decrease In Other Accounts Payable | $185.8K | -$273.7K | $7.7K | -$21.1K |
| Increase Decrease In Accounts Receivable | -$89.6K | $21.1K | $0.00 | -$971.00 |
| Proceeds From Notes Payable | $427.2K | $73.9K | ||
| Payments To Acquire Property Plant And Equipment | $189.4K | $0.00 | ||
| Payments To Acquire Intangible Assets | $0.00 | $49.4K | ||
| Increase Decrease In Inventories | -$106.4K | $36.2K | ||
| Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents | $3.0K | $18.8K | ||
| Increase Decrease In Prepaid Deferred Expense And Other Assets | -$81.8K | $119.1K | ||
| Increase Decrease In Accounts Payable Related Parties | $8.3K | $19.3K | ||
| Share Based Compensation | $2.9M | $2.2M |
Quarterly (10-Q, single quarters)
| Metric \ Quarter | Q1 2025 | Q1 2024 | Q1 2023 | Q1 2022 |
|---|---|---|---|---|
| Net Cash Provided By Used In Operating Activities | $37.7K | -$104.3K | -$566.00 | -$20.9K |
| Net Cash Provided By Used In Investing Activities | $0.00 | -$190.6K | $0.00 | $0.00 |
| Net Cash Provided By Used In Financing Activities | -$10.4K | $282.6K | -$110.00 | $0.00 |
| Increase Decrease In Deferred Revenue | -$7.7K | $2.9K | $0.00 | $8.0K |
| Increase Decrease In Other Accounts Payable | $71.0K | $129.2K | $2.6K | $6.9K |
| Increase Decrease In Accounts Receivable | -$3.8K | -$93.4K | ||
| Proceeds From Notes Payable | $0.00 | $300.0K | ||
| Payments To Acquire Property Plant And Equipment | $0.00 | $189.4K | ||
| Payments To Acquire Intangible Assets | $0.00 | $2.7K | ||
| Increase Decrease In Inventories | $29.3K | -$4.2K | ||
| Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents | -$2.1K | $1.0K | ||
| Increase Decrease In Prepaid Deferred Expense And Other Assets | -$64.3K | -$58.4K | ||
| Increase Decrease In Accounts Payable Related Parties | $265.00 | -$31.9K | ||
| Share Based Compensation | $0.00 | $1.7M |
Per-Share & Share Counts
Annual (10-K / 20-F)
| Metric \ Fiscal Year | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|
| Weighted Average Number Of Shares Outstanding Basic | 939.5M | 639.8M | 269.7M | 269.7M |
| Weighted Average Number Of Diluted Shares Outstanding | 939.5M | 639.8M | 269.7M | 269.7M |
| Earnings Per Share Diluted | $-0.02 | $-0.01 | $0.00 | $0.00 |
| Earnings Per Share Basic | $-0.02 | $-0.01 | $0.00 | $0.00 |
| Common Stock Shares Outstanding | 770.8M | 269.7M | ||
| Common Stock Shares Issued | 770.8M | 269.7M | ||
| Common Stock Shares Authorized | 1.50B | 500.0M | ||
| Common Stock Par Or Stated Value Per Share | $0.00 | $0.00 |
Quarterly (10-Q, single quarters)
| Metric \ Quarter | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q3 2023 | Q2 2023 | Q1 2023 | Q3 2022 | Q2 2022 | Q1 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Weighted Average Number Of Shares Outstanding Basic | 960.9M | 959.2M | 957.0M | 956.5M | 956.5M | 767.6M | 621.9M | 764.3M | 275.3M | 269.7M | 269.7M | 269.7M | |
| Weighted Average Number Of Diluted Shares Outstanding | 960.9M | 959.2M | 957.0M | 956.5M | 956.5M | 767.6M | 621.9M | 764.3M | 275.3M | 269.7M | 269.7M | 269.7M | |
| Earnings Per Share Diluted | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | |
| Earnings Per Share Basic | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | |
| Common Stock Shares Outstanding | 962.0M | 961.2M | 960.3M | 957.0M | 956.5M | 956.5M | 276.8M | 276.8M | 276.8M | ||||
| Common Stock Shares Issued | 962.0M | 961.2M | 960.3M | 957.0M | 956.5M | 956.5M | 276.8M | 276.8M | 276.8M | ||||
| Common Stock Shares Authorized | 1.50B | 1.50B | 1.50B | 1.50B | 1.50B | 1.50B | 500.0M | 500.0M | 500.0M | ||||
| Common Stock Par Or Stated Value Per Share | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
Other Metrics
Annual (10-K / 20-F)
| Metric \ Fiscal Year | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|
| Adjustment For Amortization | $2.2M | $0.00 | $5.9K | $4.4K |
| Additional Paid In Capital | $9.7M | $2.4M | $2.4M | |
| Interest Paid Net | $94.4K | $98.2K | $0.00 | $0.00 |
| Stock Issued During Period Value Issued For Services | $842.7K | $81.6K | ||
| Incentive Fee Expense | $173.9K | $490.8K | ||
| Issuance Of Stock And Warrants For Services Or Claims | $842.7K | $0.00 | ||
| Depreciation And Amortization | $2.2M | $4.8K | ||
| Web Design And Hosting Expense | $18.1K | $21.4K | $49.3K | |
| Programming Fees | $700.00 | $9.7K | $111.3K | |
| Professional Fees | $7.1K | $27.9K | $60.2K | |
| Professional And Contract Services Expense | $81.6K | $0.00 | $6.4K | |
| Marketing And Advertising Expense | $245.00 | $6.0K | $7.4K |
Quarterly (10-Q, single quarters)
| Metric \ Quarter | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q3 2023 | Q2 2023 | Q1 2023 | Q3 2022 | Q2 2022 | Q1 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Adjustment For Amortization | $0.00 | $562.1K | $562.1K | $0.00 | $0.00 | $1.5K | $1.5K | $1.5K | $1.5K | ||||
| Additional Paid In Capital | $31.5M | $31.4M | $31.3M | $31.0M | $29.8M | $30.0M | $3.0M | $3.0M | $3.0M | ||||
| Interest Paid Net | $23.2K | $2.9K | $0.00 | $0.00 | |||||||||
| Stock Issued During Period Value Issued For Services | $67.8K | $67.8K | $621.7K | $81.6K | |||||||||
| Incentive Fee Expense | $2.3K | $3.0K | $8.3K | $10.6K | $112.6K | $54.7K | $76.2K | ||||||
| Issuance Of Stock And Warrants For Services Or Claims | $75.6K | $621.7K | |||||||||||
| Depreciation And Amortization | $12.4K | $500.5K | |||||||||||
| Web Design And Hosting Expense | $2.8K | $4.8K | $5.1K | $3.7K | $5.3K | $7.2K | |||||||
| Programming Fees | $0.00 | $0.00 | $700.00 | $1.1K | $4.8K | $3.3K | |||||||
| Professional Fees | $0.00 | $1.8K | $0.00 | $836.00 | $18.9K | $7.9K | |||||||
| Professional And Contract Services Expense | $0.00 | $0.00 | $81.6K | $0.00 | $0.00 | $0.00 | |||||||
| Marketing And Advertising Expense | $0.00 | $33.00 | $212.00 | $0.00 | $6.0K | $12.00 |
Most recent annual filing with the SEC: April 15, 2025
Data sourced from SEC EDGAR public filings as of August 5, 2026.